Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

Although ingredient appears to be "very safe," corporate involvement and non-uniform endpoints in osteoarthritis studies make it difficult to recommend treatment, Paul Dieppe, et al., University of Bristol, England, say in June 16 British Medical Journal editorial. Rationale for glucosamine use is unclear and "appropriate dose and route of administration remain unknown," editorial points out. Although recent Lancet study demonstrated radiographic changes in cartilage, Dieppe et al. question whether such measures indicate long-term improvement and call for "large clinical trials, without company interference" (1"The Tan Sheet" Jan. 29, p. 4)

You may also be interested in...

Glucosamine Inhibits Long-Term Osteoarthritis Progression - Lancet Study

Osteoarthritis patients taking glucosamine suffered no significant joint-space loss after three years, while patients given placebo demonstrated progressive joint-space narrowing, Belgian researchers report in the Jan. 27 issue of The Lancet.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts